lung cancer
Conditions
Interventions
Sponsors
The Fifth Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in clinical research and sign written informed consent. 2. Aged 18-75 years, no gender limits. 3. Patients with stage IIIb-IV NSCLC diagnosed by histology or cytology have measurable tumor foci without chemotherapy. 4. According to recist1.1, there is at least one tumor lesion that can be repeatedly measured. 5. The expected survival time is more than 3 months. 6. ECOG status score was 0-2. 7. Organ function level must meet the following requirements: (1) Hematological indexes: absolute neutrophil count >= 1.5 x 10^9 / L, platelet count >= 75 x 10^9 / L, hemoglobin >= 80 g / L; (2) Liver function: total bilirubin <= 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST), alanine aminotransferase (ALT) <= 2.5 x ULN; (3) Renal function: serum creatinine level <= 1.5 x ULN; (4) Blood coagulation function: INR, Pt and APTT <= 1.5 times the upper limit of normal value; (5) The ECG was normal. 8. Female subjects of childbearing age must conduct serum pregnancy test within 3 days before the first administration and the result is negative. If they have sex with male partners who are not sterilized, they must take effective contraceptive methods from the beginning of screening to 120 days after the last administration, if they have sex with female partners who are not sterilized, they must take contraceptive methods from the beginning of screening to 120 days after the last administration Choose an acceptable and effective contraceptive method.
Exclusion criteria
Exclusion criteria: 1. Any unstable systemic disease (including acute infection, major cardiovascular disease {including myocardial infarction in the past year}, any serious liver, kidney or metabolic disease), metabolic disorder. 2. Except for four types of malignant tumors that can be radically resected, including cervical cancer in situ, basal or squamous cell skin cancer, intraductal carcinoma in situ (breast), and organ-limited prostate cancer, with any other malignant tumors within 5 years. 3. (Researchers believe) Patients who may transmit human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) through blood or other body fluids should be excluded. 4. Lactating and / or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progress Free Survival; | — |
Countries
China
Contacts
Public ContactLin Zhong
The Fifth Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed